Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 113   Poster Abstracts HAV and HBV: Prevention and Treatment Issues in HIV Infected Persons Wednesday, 1:30 - 3:30 pm Poster Hall

830	Response to Hepatitis A Vaccination in HIV+ Patients S Weissman*1, C Feucht2, and H Yarmohammadi3 1Hosp. of Saint Raphael New Haven, CT USA; 2Louis Stokes Cleveland VAMC, Cleveland, OH USA; and 3Mount Sinai Hosp. NYC, NY USA
831	High Incidence of Fluctuations of Hepatitis B Serum Markers in HIV-infected Patients C Manegold*, and A Apedjinou Bernhard Nocht Inst. for Tropical Med., Hamburg, Germany
832	Quantification of Hepatitis B Virus-specific T-cell Responses in HIV/HBV Co-infected Individuals J Chang1, F Wightman1, A Bartholomeusz2, A Ayres2, S J Kent3, S A Locarnini2, J Sasadeusz4, and S R Lewin*5 1Monash Univ., Melbourne, Australia; 2Victorian Infectious Diseases Reference Lab., Melbourne, Australia; 3Univ. of Melbourne, Victoria, Australia; 4Victorian Infectious Diseases Svc., Melbourne, Australia; and 5Alfred Hosp., Melbourne, Australia
833	High Prevalence of HBV Genotype E Infection in HIV-2-infected Patients Living in Southern France P Colson*1,2, M Henry1,2, S Simon1,2, N Tivoli1,2, H Gallais3, J Moreau4, J A Gastaut5, and C Tamalet1,2 1Timone Hosp.; 2CNRS UMR 6020 IFR48, Marseilles, France; 3Conception Hosp., Marseilles, France; 4North Hosp., Marseilles, France; and 5South Hosp., Marseilles, France
834	Efficacy of Tenofovir Disoproxil Fumarate in Hepatitis B Virus in HIV-co-infected Patients: The TECOVIR Study C Piketty*1, I Pellegrin2, C Katlama3, W Rozembaum4, D Neau5, G Le Teuff6, C Tamalet7, A Trylesinski1, H Fleury2, Y Benhamou3, and The Tecovir study group 1Hosp Pompidou, Paris, France; 2CHU Bordeaux, France; 3Hosp Pitie Salpetriere, Paris, France; 4Hosp Tenon, Paris, France; 5Hosp Pellegrin, Bordeaux, France; 6Cenbiothech, Dijon, France; and 7CHU Marseille, France
835	3-Year Treatment with Adefovir Dipivoxil in Chronic Hepatitis B Patients with Lamivudine-resistant HBV/HIV Co-infection, Results in Significant and Sustained Clinical Improvement Y Benhamou*1, V Thibault1, V Calvez1, P Vig2, M A Valantin1, P Guyon1, C Katlama1, B Lu2, C G Chang2, G Currie2, C L Brosgart2, and T Poynard1 1Hosp. Pitié-Salpêtrière, Paris, France and 2Gilead Sci., Inc., Foster City, CA, USA
836	Emtricitabine Therapy for Hepatitis Infection in HIV+ Patients Co-infected with Hepatitis B Virus: Efficacy and Genotypic Findings in Antiretroviral Treatment-naïve Patients A Snow, J Harris*, K Borroto-Esoda, E Mondou, J Sorbel, M Dalton, and F Rousseau Gilead Sci., Inc., Durham, NC, USA
837	Influence of HCV or HBV Infection on Efavirenz Plasma Concentrations in HIV-infected Patients J L Meynard, K Lacombe, J M Poirier, C Boudraa, L Morand-Joubert, and P M Girard* Paris France